摘要
目的研究奥扎格雷钠应用于肺源性心脏病(肺心病)急性加重期高凝状态的治疗效果。方法 86例肺心病急性加重期患者,将其随机分为对照组与观察组,各43例。对照组实施常规治疗,观察组在对照组基础上给予奥扎格雷钠治疗。观察两组患者治疗后的临床效果、凝血因子水平以及血气分析情况。结果观察组治疗后的总有效率为93.02%,高于对照组的72.09%,差异有统计学意义(P<0.05)。观察组的6-酮-前列腺素F_1α水平为(34.52±6.78)ng/L,血栓素B_2水平为(150.62±20.15)ng/L,氧分压为(9.89±0.76)kPa,二氧化碳分压为(6.37±1.26)kPa,均优于对照组的(24.14±7.06)ng/L、(178.39±25.24)ng/L、(8.31±0.65)kPa和(7.62±1.09)kPa,差异有统计学意义(P<0.05)。结论奥扎格雷钠应用于肺心病急性加重期的治疗中,能够明显控制疾病发展,改善高凝状态,值得临床推广。
Objective To research curative effect by sodium azagrel applied in treating hypercoagulable state in acute exacerbation of pulmonary heart disease.Methods A total of 86 patients with acute exacerbation of pulmonary heart disease were randomly divided into control group and observation group,with 43 cases in each group.The control group received conventional therapy,and the observation group received additional sodium ozagrel for treatment.Observation was made on clinical effect,blood coagulation factor level and blood gas analysis in both groups after treatment.Results The observation group had higher total effective rate as93.02%than 72.09%in the control group,and the difference had statistical significance（P〈0.05）.The observation group had 6- keto prostaglandin F_1α as（34.52± 6.78） ng/L,thromboxane B_2 as（150.62± 20.15） ng/L,partial pressure of oxygen as（9.89± 0.76） kPa,partial pressure of carbon dioxide as（6.37± 1.26） kPa,which were all better than（24.14± 7.06） ng/L,（178.39± 25.24） ng/L,（8.31 ± 0.65） kPa and（7.62± 1.09） kPa in the control group,and their difference had statistical significance（P〈0.05）.Conclusion Implement of sodium ozagrel in treating acute exacerbation of pulmonary heart disease can remarkably suppress disease development and improve hypercoagulable state.This method is worth clinical promotion.
出处
《中国实用医药》
2016年第33期110-111,共2页
China Practical Medicine
关键词
奥扎格雷钠
肺源性心脏病
急性加重期
高凝状态
Sodium ozagrel
Pulmonary heart disease
Acute exacerbation
Hypercoagulable state
